Predictive Biosciences Closes $25 million Series C round

June 16, 2010 by MassDevice staff

Predictive Biosciences plans to use its now-completed $25 million Series C round to begin commercializing its biomarker-based bladder cancer test.

Predictive Biosciences logo

Predictive Biosciences completed a $25 million Series C round, saying it plans to use the money to complete clinical trials for its CertNDx bladder cancer assay and ready it for market.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.